SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV

A Borghetti; Andrea CALCAGNO; F Lombardi; J Cusato; S Belmonti; A D'Avolio; N Ciccarelli; S La Monica; M Colafigli; V Delle Donne; R De Marco; E Tamburrini; E Visconti; G Di Perri; A De Luca; S Bonora; S Di Giambenedetto

doi:10.1093/jac/dky508

SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV

A Borghetti
, Andrea CALCAGNO
, F Lombardi
, J Cusato
, S Belmonti
, A D'Avolio
, N Ciccarelli
, S La Monica
, M Colafigli
, V Delle Donne
, R De Marco
, E Tamburrini
, E Visconti
, G Di Perri
, A De Luca
, S Bonora
, S Di Giambenedetto

Dipartimento di Medicina Traslazionale

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

Abstract

Neuropsychiatric symptoms (NPs) have been reported with dolutegravir use. We hypothesized that increasing dolutegravir trough concentrations (Ctrough) and/or polymorphism in the SLC22A2 gene, encoding the organic cation transporter-2 (OCT2), which is involved in monoamine clearance in the CNS and is inhibited by dolutegravir, might be associated with NPs.

Lingua originale	Inglese
pagine (da-a)	1035-1043
Numero di pagine	9
Rivista	Journal of Antimicrobial Chemotherapy
Volume	74
Numero di pubblicazione	4
DOI	https://doi.org/10.1093/jac/dky508
Stato di pubblicazione	Pubblicato - 2019

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

SDG 3 Salute e benessere

Accesso al documento

10.1093/jac/dky508

https://hdl.handle.net/11579/216909

Altri file e collegamenti

handle

Cita questo

Borghetti, A., CALCAGNO, A., Lombardi, F., Cusato, J., Belmonti, S., D'Avolio, A., Ciccarelli, N., La Monica, S., Colafigli, M., Delle Donne, V., De Marco, R., Tamburrini, E., Visconti, E., Di Perri, G., De Luca, A., Bonora, S., & Di Giambenedetto, S. (2019). SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV. Journal of Antimicrobial Chemotherapy, 74(4), 1035-1043. https://doi.org/10.1093/jac/dky508

@article{c54cb38248a34cc2a899dea669fcbc77,

title = "SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV",

abstract = "Neuropsychiatric symptoms (NPs) have been reported with dolutegravir use. We hypothesized that increasing dolutegravir trough concentrations (Ctrough) and/or polymorphism in the SLC22A2 gene, encoding the organic cation transporter-2 (OCT2), which is involved in monoamine clearance in the CNS and is inhibited by dolutegravir, might be associated with NPs.",

author = "A Borghetti and Andrea CALCAGNO and F Lombardi and J Cusato and S Belmonti and A D'Avolio and N Ciccarelli and \{La Monica\}, S and M Colafigli and \{Delle Donne\}, V and \{De Marco\}, R and E Tamburrini and E Visconti and \{Di Perri\}, G and \{De Luca\}, A and S Bonora and \{Di Giambenedetto\}, S",

year = "2019",

doi = "10.1093/jac/dky508",

language = "English",

volume = "74",

pages = "1035--1043",

journal = "Journal of Antimicrobial Chemotherapy",

issn = "0305-7453",

publisher = "Oxford University Press",

number = "4",

}

Borghetti, A, CALCAGNO, A, Lombardi, F, Cusato, J, Belmonti, S, D'Avolio, A, Ciccarelli, N, La Monica, S, Colafigli, M, Delle Donne, V, De Marco, R, Tamburrini, E, Visconti, E, Di Perri, G, De Luca, A, Bonora, S & Di Giambenedetto, S 2019, 'SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV', Journal of Antimicrobial Chemotherapy, vol. 74, n. 4, pagg. 1035-1043. https://doi.org/10.1093/jac/dky508

TY - JOUR

T1 - SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV

AU - Borghetti, A

AU - CALCAGNO, Andrea

AU - Lombardi, F

AU - Cusato, J

AU - Belmonti, S

AU - D'Avolio, A

AU - Ciccarelli, N

AU - La Monica, S

AU - Colafigli, M

AU - Delle Donne, V

AU - De Marco, R

AU - Tamburrini, E

AU - Visconti, E

AU - Di Perri, G

AU - De Luca, A

AU - Bonora, S

AU - Di Giambenedetto, S

PY - 2019

Y1 - 2019

N2 - Neuropsychiatric symptoms (NPs) have been reported with dolutegravir use. We hypothesized that increasing dolutegravir trough concentrations (Ctrough) and/or polymorphism in the SLC22A2 gene, encoding the organic cation transporter-2 (OCT2), which is involved in monoamine clearance in the CNS and is inhibited by dolutegravir, might be associated with NPs.

AB - Neuropsychiatric symptoms (NPs) have been reported with dolutegravir use. We hypothesized that increasing dolutegravir trough concentrations (Ctrough) and/or polymorphism in the SLC22A2 gene, encoding the organic cation transporter-2 (OCT2), which is involved in monoamine clearance in the CNS and is inhibited by dolutegravir, might be associated with NPs.

UR - https://iris.uniupo.it/handle/11579/216909

U2 - 10.1093/jac/dky508

DO - 10.1093/jac/dky508

M3 - Article

SN - 0305-7453

VL - 74

SP - 1035

EP - 1043

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

IS - 4

ER -

SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV

Abstract

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo